全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

The Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012

DOI: 10.1155/2013/702167

Full-Text   Cite this paper   Add to My Lib

Abstract:

Neuroendocrine tumors (NETs) comprise a heterogeneous group of tumors that form a distinct entity. Approximately 75–80% of patients present with liver metastases at the time of their diagnosis, and 20%–25% will develop these lesions in the course of their disease. The presence of secondary deposits in the liver significantly increases the morbidity and mortality in these patients. The only potentially curative treatment is the surgical resection of the primary tumor and hepatic lesions. However, only 10% of patients presents under ideal conditions for that approach. Several techniques aimed at localized liver lesions have been applied also with interesting results in terms of survival and symptom control. The same has been demonstrated with new systemic therapies (target therapies). However, these are still under study, in order to define their true role in the management of these patients. This paper intends to address, in a general way, the various treatment options in patients with liver metastases from neuroendocrine tumors. 1. Introduction The neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms that share some biological characteristics, that have been addressed as a common entity [1]. In 62%–82% of the cases, the NETs are located in the digestive system, being designated as gastroenteropancreatic neuroendocrine tumors (GEP-NETs) [2]. The latest figures from the UK, Sweden, and Switzerland suggested that their incidence is 2-3/100000 with a higher prevalence in females [1]. Also data from the Surveillance, Epidemiology, and End Results (SEER) Program Database report an increased incidence between 1973 and 2004 of 1.09 to 5,25/100000 [3, 4]. NETs are classically characterized by their ability to secrete hormones and/or vasoactive peptides, which results in many of their clinical manifestations, ganging up on specific hormonal syndromes. The most frequent syndrome is the carcinoid syndrome, which results from the secretion of serotonin and includes symptoms such as skin flushing, severe diarrhea, abdominal cramping, and electrolyte abnormalities [4, 5]. Their clinical course is variable, having been considered traditionally with an indolent natural history [1, 4]. However, some NETs have aggressive behavior regarding the rapid progression of metastatic lesions. All of them have the potential of metastatic dissemination and, therefore, are currently recognized as malignant neoplasms [6]. The prognosis and the approach of NETs are guided mainly according to the histological classification. The tumors with grade 3, mitotic count

References

[1]  J. K. Ramage, A. Ahmed, J. Ardill, et al., “Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumors (NETs),” An International Journal of Gastroenterology and Hepatology, vol. 61, pp. 6–32, 2012.
[2]  I. M. Modlin, K. Oberg, D. C. Chung et al., “Gastroenteropancreatic neuroendocrine tumours,” The Lancet Oncology, vol. 9, no. 1, pp. 61–72, 2008.
[3]  J. C. Yao, M. Hassan, A. Phan et al., “One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States,” Journal of Clinical Oncology, vol. 26, no. 18, pp. 3063–3072, 2008.
[4]  P. Gu, J. Wu, E. Newman, and F. Muggia, “Treatment of liver metastases in patients with neuroendocrine tumors of gastroesophageal and pancreatic origin,” International Journal of Hepatology, vol. 2012, Article ID 131659, 8 pages, 2012.
[5]  E. Lee, H. L. Pachter, and U. Sarpel, “Hepatic arterial embolization for the treatment of metastatic neuroendocrine tumors,” International Journal of Hepatology, vol. 2012, Article ID 471203, 8 pages, 2012.
[6]  P. Jagannath, D. Chhlabra, Shirkhande, and R. Shah, “Surgical treatment of liver metastases in neuroendocrine neoplasms,” International Journal of Hepatology, vol. 2012, Article ID 782672, 9 pages, 2012.
[7]  A. P. Venook, “Embolization and chemoembolization therapy for neuroendocrine tumors,” Current Opinion in Oncology, vol. 11, no. 1, pp. 38–41, 1999.
[8]  I. M. Modlin, K. D. Lye, and M. Kidd, “A 5-decade analysis of 13,715 carcinoid tumors,” Cancer, vol. 97, no. 4, pp. 934–959, 2003.
[9]  J. G. Touzios, J. M. Kiely, S. C. Pitt et al., “Neuroendocrine hepatic metastases: does aggressive management improve survival?” Annals of Surgery, vol. 241, no. 5, pp. 776–785, 2005.
[10]  M. Mignon, “Natural history of neuroendocrine enteropancreatic tumors,” Digestion, vol. 62, no. 1, pp. 51–58, 2000.
[11]  A. Frilling, G. C. Sotiropoulos, J. Li, O. Kornasiewicz, and U. Pl?ckinger, “Multimodal management of neuroendocrine liver metastases,” Hepato-Pancreato-Biliary, vol. 12, no. 6, pp. 361–379, 2010.
[12]  T. R. Harring, N. T. N. Nguyen, J. A. Goss, and C. A. O’Mahony, “Treatment of liver metastases in patients with neuroendocrine tumors: a comprehensive review,” International Journal of Hepatology, vol. 2011, Article ID 154541, 11 pages, 2011.
[13]  J. R. Strosberg, A. Cheema, and L. K. Kvols, “A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract,” Cancer Control, vol. 18, no. 2, pp. 127–137, 2011.
[14]  M. A. Lewis and J. Hubbard, “Multimodal liver-directed management of neuroendocrine hepatic metastases,” International Journal of Hepatology, vol. 2011, Article ID 452343, 12 pages, 2011.
[15]  H. Cerwenka, “Neuroendocrine liver metastases: contributions of endoscopy and surgery to primary tumor search,” World Journal of Gastroenterology, vol. 18, no. 10, pp. 1009–1014, 2012.
[16]  J. C. Yao, C. Lombard-Bohas, E. Baudin et al., “Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial,” Journal of Clinical Oncology, vol. 28, no. 1, pp. 69–76, 2010.
[17]  M. S. Khan and M. E. Caplin, “Therapeutic management of patients with gastroenteropancreatic neuroendocrine tumours,” Endocrine-Related Cancer, vol. 18, supplement 1, pp. S53–S74, 2011.
[18]  R. C. Roy, R. F. Carter, and P. D. Wright, “Somatostatin, anaesthesia, and the carcinoid syndrome. Peri-operative administration of a somatostatin analogue to suppress carcinoid tumour activity,” Anaesthesia, vol. 42, no. 6, pp. 627–632, 1987.
[19]  C. Bassi, M. Falconi, and P. Pederzoli, “Role of somatostatin and somatostatin analogues in the treatment of gastrointestinal diseases: prevention of complications after pancreatic surgery,” Gut, vol. 35, no. 3, supplement, pp. S20–S22, 1994.
[20]  J. M. Sarmiento and F. G. Que, “Hepatic surgery for metastases from neuroendocrine tumors,” Surgical Oncology Clinics of North America, vol. 12, no. 1, pp. 231–242, 2003.
[21]  R. S. Charberlain, D. Canes, K. T. Brown, et al., “Hepatic neuroendocrine metastases: does intervention alter aoutcomes?” Journal of the American College of Surgeons, vol. 190, pp. 432–445, 2000.
[22]  K. ?berg, L. Kvols, M. Caplin et al., “Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system,” Annals of Oncology, vol. 15, no. 6, pp. 966–973, 2004.
[23]  R. R. P. Warner, S. Mani, J. Profeta, and E. Grunstein, “Octreotide treatment of carcinoid hypertensive crisis,” Mount Sinai Journal of Medicine, vol. 61, no. 4, pp. 349–355, 1994.
[24]  I. Fernandes, T. Amaral, D. Macedo, P. Cortes, and L. Costa, “Op??es terapêuticas em carcinomas neuroendócrinos gastroenteropancreáticos (GEP NETS) metastáticos,” Revista Portuguesa de Cirurgia, no. 16, pp. 47–54, 2011.
[25]  H. Chen, J. M. Hardacre, A. Uzar, J. L. Cameron, and M. A. Choti, “Isolated liver metastases from neuroendocrine tumors: does resection prolong survival?” Journal of the American College of Surgeons, vol. 187, no. 1, pp. 88–93, 1998.
[26]  H. Ahlman, B. W?ngberg, S. Jansson et al., “Interventional treatment of gastrointestinal neuroendocrine tumours,” Digestion, vol. 62, supplement 1, pp. 59–68, 2000.
[27]  T. Lehnert, “Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients,” Transplantation, vol. 66, no. 10, pp. 1307–1312, 1998.
[28]  Y. P. Le Treut, E. Grégoire, J. Belghiti et al., “Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: an 85-case French multicentric report,” The American Journal of Transplantation, vol. 8, no. 6, pp. 1205–1213, 2008.
[29]  Z. Máthé, E. Tagkalos, A. Paul et al., “Liver transplantation for hepatic metastases of neuroendocrine pancreatic tumors: a survival-based analysis,” Transplantation, vol. 91, no. 5, pp. 575–582, 2011.
[30]  A. J. Bilchik, T. Sarantou, L. J. Foshag, A. E. Giuliano, and K. P. Ramming, “Cryosurgical palliation of metastatic neuroendocrine tumors resistant to conventional therapy,” Surgery, vol. 122, no. 6, pp. 1040–1048, 1997.
[31]  Y. Li, F. Wang, and H. Wang, “Cell death along single microfluidic channel after freeze-thaw treatments,” Biomicrofluidics, vol. 4, no. 1, Article ID 014111, 10 pages, 2010.
[32]  A. A. Gage and J. Baust, “Mechanisms of tissue injury in cryosurgery,” Cryobiology, vol. 37, no. 3, pp. 171–186, 1998.
[33]  M. Giovannini, “Percutaneous alcohol ablation for liver metastasis,” Seminars in Oncology, vol. 29, no. 2, pp. 192–195, 2002.
[34]  R. Gedaly, M. F. Daily, D. Davenport, et al., “Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database,” Archives of Surgery, vol. 146, no. 8, pp. 953–958, 2011.
[35]  T. D. Atwell, J. W. Charboneau, F. G. Que et al., “Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques,” CardioVascular and Interventional Radiology, vol. 28, no. 4, pp. 409–421, 2005.
[36]  E. Berber and A. Siperstein, “Local recurrence after laparoscopic radiofrequency ablation of liver tumors: an analysis of 1032 tumors,” Annals of Surgical Oncology, vol. 15, no. 10, pp. 2757–2764, 2008.
[37]  G. Poncet, J. L. Faucheron, and T. Walter, “Recent trends in the treatment of well-differentiated endocrine carcinoma of the small bowel,” World Journal of Gastroenterology, vol. 16, no. 14, pp. 1696–1706, 2010.
[38]  A. Saxena, T. C. Chua, A. Sarkar et al., “Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach,” Surgery, vol. 149, no. 2, pp. 209–220, 2011.
[39]  A. S. Kennedy, W. A. Dezarn, P. McNeillie et al., “Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients,” American Journal of Clinical Oncology, vol. 31, no. 3, pp. 271–279, 2008.
[40]  W. Bauer, U. Briner, W. Doepfner, et al., “SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action,” Life Sciences, vol. 31, no. 11, pp. 1133–1140, 1982.
[41]  A. Rinke, H. H. Müller, C. Schade-Brittinger et al., “Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group,” Journal of Clinical Oncology, vol. 27, no. 28, pp. 4656–4663, 2009.
[42]  D. J. Kwekkeboom, E. P. Krenning, K. Scheidhauer, et al., “ENETS consensus guidelines for standard of care in neuroendocrine tumors: somatostatine receptor imaging with 111In- penteotride,” Neuroendocrinology, vol. 90, no. 2, pp. 184–189, 2009.
[43]  C. D. Knox, I. D. Feurer, P. E. Wise et al., “Survival and functional quality of life after resection for hepatic carcinoid metastasis,” Journal of Gastrointestinal Surgery, vol. 8, no. 6, pp. 653–659, 2004.
[44]  F. Gibril, J. C. Reynolds, J. L. Doppman et al., “Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas—a prospective study,” Annals of Internal Medicine, vol. 125, no. 1, pp. 26–34, 1996.
[45]  B. Givi, S. J. Pommier, A. K. Thompson, B. S. Diggs, and R. F. Pommier, “Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival,” Surgery, vol. 140, no. 6, pp. 891–898, 2006.
[46]  O. Soreide, T. Berstad, A. Bakka et al., “Surgical treatment as a principle in patients with advanced abdominal carcinoid tumors,” Surgery, vol. 111, no. 1, pp. 48–54, 1992.
[47]  A. E. Siperstein, S. J. Rogers, P. D. Hansen, and A. Gitomirsky, “Laparoscopic thermal ablation of hepatic neuroendocrine tumor metastases,” Surgery, vol. 122, no. 6, pp. 1147–1155, 1997.
[48]  L. K?lby, G. Persson, S. Franzén, and B. Ahrén, “Randomized clinical trial of the effect of interferon α on survival in patients with disseminated midgut carcinoid tumours,” British Journal of Surgery, vol. 90, no. 6, pp. 687–693, 2003.
[49]  S. Faiss, U. F. Pape, M. B?hmig et al., “Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors—The International Lanreotide and Interferon Alfa Study Group,” Journal of Clinical Oncology, vol. 21, no. 14, pp. 2689–2696, 2003.
[50]  R. Arnold, A. Rinke, K. J. Klose et al., “Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial,” Clinical Gastroenterology and Hepatology, vol. 3, no. 8, pp. 761–771, 2005.
[51]  G. A. Kaltsas, D. Papadogias, P. Makras, and A. B. Grossman, “Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues,” Endocrine-Related Cancer, vol. 12, no. 4, pp. 683–699, 2005.
[52]  M. Khasraw, A. Gill, T. Harrington, N. Pavlakis, and I. Modlin, “Management of advanced neuroendocrine tumors with hepatic metastasis,” Journal of Clinical Gastroenterology, vol. 43, no. 9, pp. 838–847, 2009.
[53]  M. van Essen, E. P. Krenning, M. de Jong, R. Valkema, and D. J. Kwekkeboom, “Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours,” Acta Oncologica, vol. 46, no. 6, pp. 723–734, 2007.
[54]  R. K. Ramanathan, A. Cnaan, R. G. Hahn, P. P. Carbone, and D. G. Haller, “Phase II trial dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282,” Annals of Oncology, vol. 12, no. 8, pp. 1139–1143, 2001.
[55]  M. H. Kulke, K. Stuart, P. C. Enzinger et al., “Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors,” Journal of Clinical Oncology, vol. 24, no. 3, pp. 401–406, 2006.
[56]  J. R. Strosberg, R. L. Fine, J. Choi et al., “First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas,” Cancer, vol. 117, no. 2, pp. 268–275, 2011.
[57]  E. Mitry, E. Baudin, M. Ducreux et al., “Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin,” The British Journal of Cancer, vol. 81, no. 8, pp. 1351–1355, 1999.
[58]  C. G. Moertel, L. K. Kvols, M. J. O’Connel, and J. Rubin, “Treatment of neuroendocrine carcinomas with combined etoposide and cisplatine. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms,” Cancer, vol. 68, no. 2, pp. 227–232, 1991.
[59]  M. L. Fjallskog, D. P. K. Granberg, S. L. V. Welin, et al., “Treatment with cisplatin and etoposide in patients with neuroendocrine tumors,” Cancer, vol. 92, no. 5, pp. 1101–1107, 2001.
[60]  E. Bajetta, L. Catena, G. Procopio et al., “Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?” Cancer Chemotherapy and Pharmacology, vol. 59, no. 5, pp. 637–642, 2007.
[61]  J. C. Yao, A. Phan, P. M. Hoff et al., “Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase ii study of depot octreotide with bevacizumab and pegylated interferon alfa-2b,” Journal of Clinical Oncology, vol. 26, no. 8, pp. 1316–1323, 2008.
[62]  E. Raymond, L. Dahan, J. L. Raoul et al., “Sunitinib malate for the treatment of pancreatic neuroendocrine tumors,” The New England Journal of Medicine, vol. 364, no. 6, pp. 501–513, 2011.
[63]  J. C. Yao, M. H. Shah, T. Ito et al., “Everolimus for advanced pancreatic neuroendocrine tumors,” The New England Journal of Medicine, vol. 364, no. 6, pp. 514–523, 2011.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133